Paper Details

  1. Home
  2. Paper Details

Prognostic factors in multiple myeloma in a population-based trial.

Author: GrøttumK A, HannisdalE, Kildahl-AndersenO, LamvikJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated factors that predict survival in 92 patients with multiple myeloma. The study found that older age (over 70 years), anemia, kidney problems, and bone lesions were associated with a poorer prognosis. The study also found that a staging system developed by the Medical Research Council (MRC) was a more accurate predictor of survival compared to a different staging system. The study concludes that for older patients with multiple myeloma, treatment strategies should consider the impact on quality of life.
Paper Details　
Original Abstract of the Article :
Prognostic factors have been tested in patients with multiple myeloma treated according to a randomized trial of standard therapy versus 5-drug combination therapy. The following population-based study included 92 patients with a median age of 70 yr. The median survival was 31 months. The Cox regres...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1600-0609.1990.tb00457.x

データ提供：米国国立医学図書館（NLM）

Unveiling the Landscape of Multiple Myeloma

Multiple myeloma, a complex and challenging cancer, requires a comprehensive understanding of its various facets. This study explores the prognostic factors that influence patient survival in multiple myeloma. The researchers analyzed data from a population-based trial involving 92 patients treated with either standard therapy or a 5-drug combination therapy. The study revealed that factors such as lytic bone lesions, age, anemia, and impaired renal function play a crucial role in predicting patient outcomes. The researchers also found that the MRC staging system provided a more accurate prognostic tool than the Durie & Salmon stages.

Navigating the Shifting Sands of Multiple Myeloma

This study underscores the importance of identifying prognostic factors in multiple myeloma. By understanding these factors, healthcare professionals can tailor treatment plans to individual patients, maximizing their chances of survival. The study also highlights the need for continued research to develop more effective therapies and improve the quality of life for patients facing this challenging disease.

Personalized Treatment for Multiple Myeloma

The findings emphasize the need for a personalized approach to multiple myeloma treatment. By carefully evaluating prognostic factors, healthcare professionals can tailor therapies to individual patients, ensuring that they receive the most effective and appropriate care. This personalized approach, much like a skilled desert guide leading a caravan through varied terrain, can help patients navigate the challenges of multiple myeloma.

Dr.Camel's Conclusion

This study provides valuable insight into the complexities of multiple myeloma, highlighting the need for a personalized and proactive approach to treatment. By carefully considering prognostic factors and customizing therapy accordingly, we can offer a more tailored and effective path through the desert of cancer.

Date :
  1. Date Completed 1990-12-10
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

2226737

DOI: Digital Object Identifier

10.1111/j.1600-0609.1990.tb00457.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.